Genmab A/S’s (GMAB) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Genmab A/S (NASDAQ:GMAB) in a research report report published on Tuesday, Benzinga reports. They currently have a $50.00 price target on the stock.

Several other brokerages have also recently issued reports on GMAB. Truist Financial reiterated a buy rating and issued a $50.00 price objective on shares of Genmab A/S in a research note on Tuesday, March 26th. BMO Capital Markets upgraded Genmab A/S from a market perform rating to an outperform rating and boosted their target price for the stock from $46.00 to $48.00 in a research note on Friday, February 23rd. Citigroup cut Genmab A/S from a neutral rating to a sell rating in a research note on Monday, January 22nd. Finally, Morgan Stanley reiterated an underweight rating on shares of Genmab A/S in a research note on Tuesday, March 26th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of Hold and a consensus price target of $48.50.

Genmab A/S Stock Performance

Shares of GMAB opened at $27.69 on Tuesday. The stock has a 50-day simple moving average of $29.41 and a 200-day simple moving average of $29.94. The stock has a market capitalization of $18.31 billion, a PE ratio of 28.84, a PEG ratio of 2.02 and a beta of 0.98. Genmab A/S has a 1 year low of $26.32 and a 1 year high of $42.72.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Wednesday, February 14th. The company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.02. The business had revenue of $675.29 million during the quarter, compared to analysts’ expectations of $678.14 million. Genmab A/S had a return on equity of 18.06% and a net margin of 26.50%. Analysts predict that Genmab A/S will post 1.06 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Headlands Technologies LLC acquired a new position in Genmab A/S during the third quarter worth $27,000. Pinnacle Bancorp Inc. grew its holdings in Genmab A/S by 315.8% during the fourth quarter. Pinnacle Bancorp Inc. now owns 840 shares of the company’s stock worth $27,000 after acquiring an additional 638 shares during the period. GAMMA Investing LLC grew its holdings in Genmab A/S by 194.0% during the first quarter. GAMMA Investing LLC now owns 1,135 shares of the company’s stock worth $34,000 after acquiring an additional 749 shares during the period. NBC Securities Inc. acquired a new position in Genmab A/S during the third quarter worth $37,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Genmab A/S by 86.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,075 shares of the company’s stock worth $38,000 after acquiring an additional 498 shares during the period. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.